ONK Therapeutics News:
We are hiring!
Further details available on LInkedIN
Press Release 06th May. 2020
ONK Therapeutics and biotech company Avectas has signed a collaborative deal for Avectas to licence a therapy from ONK Therapeutics that targets blood cell cancers such as non-Hodgkin’s lymphoma and certain forms of leukaemia.
Read the full article here
Press Release 10th Dec. 2018
ONK Therapeutics announced as one of the 27 ground breaking projects to receive funding Under Disruptive Technologies Innovation Fund
Today, The Department for Business, Enterprise and Innovation through the Disruptive Technologies Innovation Fund announced that Galway based ONK Therapeutics Ltd, together with it’s consortium partners Janssen Sciences Ireland UC based in Cork and the Centre for Cell Manufacturing Ireland based at NUI Galway, are one of it’s 27 chosen projects to receive funding in order to further develop it’s research into the treatment of cancer, the second biggest killer of humans globally.
ONK Therapeutics is an NK cell therapy company focused on cancer treatment. NK cells are one of the body’s strongest defences against cancer, being one of the most tumour cytotoxic components of the human immune system. ONK Therapeutics’s strategy is to develop novel, off the shelf, NK cell-based therapies for cancer. Further, the company is seeking to enhance these NK cells through the introduction of a series of genetic modifications, creating a technology platform that can be tailored to multiple cancers.
Following this morning’s announcement by An Taoiseach, Leo Varadkar TD and Minister for Business, Enterprise and Innovation, Heather Humphreys, Professor Michael O’Dwyer, Chief Scientific Officer of ONK Therapeutics welcomed the announcement and said that he looked forward to developing novel NK cell based therapeutics for cancer in collaboration with consortium partners, NUI Galway and Janssen.
For further information please contact:
Prof. Michael O’Dwyer
Founder & Director of ONK Therapeutics
Tel: +353 87 250 6638